Biomea Fusion, Inc. (BMEA)
1.14
-0.01 (0.87%)
Upcoming Events
Latest Headlines
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 S
June 5, 2026 7:32 PM - StreetInsider
Biomea Fusion partners with University of Leicester for obesity study
June 3, 2026 8:03 AM - StreetInsider
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
June 3, 2026 8:00 AM - StreetInsider
Biomea Fusion to Participate at Upcoming Investor Conferences
May 12, 2026 4:05 PM - StreetInsider
Biomea Fusion, Inc. (BMEA) Tops Q1 EPS by 6c
May 11, 2026 5:39 PM - StreetInsider
Form 10-Q Biomea Fusion, Inc. For: Mar 31
May 11, 2026 5:02 PM - SEC Filing
Form 8-K Biomea Fusion, Inc. For: May 11
May 11, 2026 4:58 PM - SEC Filing
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
May 11, 2026 4:54 PM - Globe NewsWire
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
May 5, 2026 5:50 PM - Globe NewsWire
Citizens Starts Biomea Fusion Inc. (BMEA) at Market Outperform
May 5, 2026 2:51 AM - StreetInsider
Form 8-K Biomea Fusion, Inc. For: Apr 27
April 28, 2026 8:30 AM - SEC Filing
Biomea Fusion reports icovamenib shows C-peptide gains in type 1 diabetes
April 27, 2026 5:37 PM - StreetInsider
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
April 27, 2026 5:37 PM - Globe NewsWire
Form DEF 14A Biomea Fusion, Inc. For: Jun 10
April 27, 2026 4:09 PM - SEC Filing
Form ARS Biomea Fusion, Inc. For: Dec 31
April 27, 2026 4:05 PM - SEC Filing
Biomea Fusion, Inc. (BMEA) October 2.5 calls active, share price down 7.8%
April 8, 2026 3:35 PM - StreetInsider
Form 4 Biomea Fusion, Inc. For: Apr 01 Filed by: Erdtmann Rainer M
April 3, 2026 4:15 PM - SEC Filing
Form 4 Biomea Fusion, Inc. For: Apr 01 Filed by: Hitchcock Michael J.M.
April 3, 2026 4:15 PM - SEC Filing
Biomea Fusion doses first patient in phase II diabetes studies
March 31, 2026 7:01 AM - StreetInsider
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
March 31, 2026 7:00 AM - StreetInsider
Biomea Fusion Inc. (BMEA) PT Raised to $7 at Citi, Opens Catalyst Watch
March 26, 2026 9:10 AM - StreetInsider
Form 10-K Biomea Fusion, Inc. For: Dec 31
March 24, 2026 4:12 PM - SEC Filing
Form 8-K Biomea Fusion, Inc. For: Mar 24
March 24, 2026 4:10 PM - SEC Filing
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
March 24, 2026 4:05 PM - StreetInsider
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
March 14, 2026 4:30 AM - Globe NewsWire
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
March 14, 2026 4:30 AM - StreetInsider
Full Article List